What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Perrot et al. Factors assoc severe COVID in SpA. corticosteroid intake (3.15 [1.46-6.76]), age (OR=1.06 [1.04-1.08]) while anti-TNF (OR=0.26 [0.09-0.78]) was protective @RheumNow #EULAR2022 OP0254 https://t.co/bIiEW6efQ2
Janet Pope Janetbirdope
3 years 6 months ago
A new finding - antimalarials improve safety w bDMARDs & #JAKi and reduce CV events and improve drug survival #Bestinclass. POS0242 @RheumNow @eular_org #EULAR2022 Neat. Safe, inexpensive and monitor eyes 👀 https://t.co/Ea4VA9vqwe
Robert B Chao, MD doctorRBC
3 years 6 months ago
Large 5 country cohort study - No increased risk of hematologic malignancies (lymphoid or myeloid) in PsA pts treated with TNFi.
In PsA overall compared to general population - moderately increased underlying risk of hematologic malignancies.
@RheumNow #EULAR2022 ABST#OP0257 https://t.co/P846RupitR
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#OP0783 #EULAR2022 A study in Spain (N=72) of #Sjogren pts showed Pathologic US of salivary glands were associated with Ro52+, raised IgG, early menopause & lack Mediterranean diet. Smoking was protective but wide Confidence Interval. I wont promote smoking though @RheumNow https://t.co/kn4X4oFGzK
Dr. Rachel Tate uptoTate
3 years 6 months ago
Female PsA patients on TNFi have reduced treatment effectiveness, LDA (vs males). #EULAR2022 POS0077 @RheumNow https://t.co/EwDwxUarNb https://t.co/W5xgQlrnlF
David Liew drdavidliew
3 years 6 months ago
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
Janet Pope Janetbirdope
3 years 6 months ago
#ClinicalPearl. Why do doctors prescribe #JAKi in RA? Efficacy, fast onset, X-ray inhibition, can work as monotherapy, remission - in order of diminishing frequency BUT I will add access and oral (convenience). POS0680 @RheumNow @eular_org #EULAR2022 https://t.co/XHtNqguqvh
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 Telemedicine: PROs
💻Triage, reduce wait time, direct other specialty referral
💻High agreement w F2F evaluation (79-97%)
💻Saves resources, react quickly to minor flare
💻Better adherence
@RheumNow
Janet Pope Janetbirdope
3 years 6 months ago
BTKi are they effective in #rheumatology? Seem to work in preclinical models of inflammation but so far clinical results seem disappointing #POS0397 @RheumNow @eular_org #EULAR2022 https://t.co/2NjcMnU1d6
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022
R Landewe: Anti-Telemedicine
🩺Rheumatology about long-term relationship & communication
🩺"Telemedicine impoverishes visit" by only exchanging information
@Rheumnow
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS0752 #EULAR2022 Is there difference btw childhood- vs adult-onset #lupus?A cohort study of claims database >10,000 pts showed:
Children had higher activity & more likely to receive immunosuppressant
Some activities persisted
Useful to bear in transition clinic @RheumNow https://t.co/KVHZUgAOlV
Robert B Chao, MD doctorRBC
3 years 6 months ago
Inflammation (ESR >20 and cardiovascular risk scores) in AxSpA pts associated with incident hypertension.
csDMARD may be associated with HTN
NSAID and biologics not associated with incident HTN
@RheumNow #EULAR2022 ABST#POS0154 https://t.co/5pYjXrpCec
TheDaoIndex KDAO2011
3 years 6 months ago
#PEARLS by EULAR President Prof Iagnocco:
1. Enthesitis can be present in 25% of #SLE patients
2. Erosions can be common and independent of ACPA/RF status
3. Active myositis is indistinguishable from IIM
4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH
TheDaoIndex KDAO2011
3 years 6 months ago
Staggering facts by Prof Vital on #SLE and SkM Sx’s:
- 50% of first Sx’s is SkM
- SkM Sx are in top 3 concerns for pts
- 34% pts w/SkM Sx stopped working median 4 yrs
- SkM damage clusters with CVD damage
#EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ
Poster Hall